Reduced immunogenicity of MYC amplified, metastatic prostate cancer (IMAGE)
Caption
Box and whisker plots of selected immune marker genes for comparison of expression levels (tpm and fpkm) for MYC amplified (shaded) and non-amplified WCDT-MCRPC cases.
( A ) tpm: CD19, p -value = 0.004; CD22, p -value <0.001; CD33, p-value = 0.004; CD68, p-value = 0.006; CD79B, p-value=0.007; MS4A1, p-value = 0.002; SPHK1, p-value = 0.037. ( B ) tpm: CD4, p-value = 0.038; CD79A, p-value = 0.005; CIITA, p-value = 0.017; CTSC, p-value = 0.018; ITGAX, p-value = 0.010. ( C ) fpkm: CD19, p-value = 0.002; CD22, p-value <0.001; CD33, p-value = 0.002; CD68, p-value = 0.004; CD79B, p-value = 0.004; MS4A1, p-value = 0.002; SPHK1, p-value = 0.021. ( D ) fpkm: CD4, p -value = 0.017; CD79A, p -value = 0.007; CIITA, p -value = 0.023; CTSC, p -value = 0.012; ITGAX, p-value = 0.013. For the full range of RNA-seq data corresponding to the specified immune marker genes, along with data for other immune marker genes refer to Supplementary Table 7.
Credit
Copyright: © 2026 Kahlon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content